李炳冰 张明军

    [摘要]?目的?比較免疫检查点抑制剂(immune?checkpoint?inhibitor，ICI)联合放化疗与同步放化疗治疗晚期食管癌的疗效及安全性。方法?回顾性分析2019年1月至2023年1月于安徽医科大学第二附属医院接受治疗的67例晚期食管癌患者的临床资料。根据治疗方案不同将纳入患者分为联合组(n=35)和放化疗组(n=32)。比较两组患者的无进展生存(progress?free?survive，PFS)、客观缓解率(objective?remission?rate，ORR)、疾病控制率(disease?control?rate，DCR)和不良反应。结果?联合组患者的中位PFS显著长于放化疗组(12.6个月?vs.?6.3个月，χ2=16.288，P<0.001)；联合组患者的ORR显著高于放化疗组(54.3%?vs.?21.9%，P=0.011)；联合组患者的DCR显著高于放化疗组(77.1%?vs.?53.1%，P=0.045)。联合组患者的治疗相关不良反应及放化疗相关不良反应发生率均显著低于放化疗组(P<0.05)；联合组出现免疫相关不良反应11例，均为1～2级不良反应。结论?ICI联合放化疗可提高晚期食管癌患者的疗效，不良反应可接受。

    [关键词]?食管癌；免疫检查点抑制剂；不良反应；疗效

    [中图分类号]?R735.1?[文献标识码]?A?&nbsp;[DOI]?10.3969/j.issn.1673-9701.2024.01.010

    A?retrospective?study：?The?efficacy?and?safety?of?immunotherapy?combined?with?radiochemotherapy?for?advanced?esophageal?cancer

    LI?Bingbing，?ZHANG?Mingjun

    Department?of?Medical?Oncology，?the?Second?Hospital?of?Anhui?Medical?University，?Hefei?230601，?Anhui，?China

    [Abstract]?Objective?To?contrast?the?efficacy?and?safety?of?immune?checkpoint?inhibitor?(ICI)?combined?with?radiochemotherapy?and?concomitant?radiochemotherapy?in?the?treatment?of?advanced?esophageal?cancer.?Methods?The?clinical?data?of?67?patients?with?advanced?esophageal?cancer?who?were?treated?in?the?Second?Hospital?of?Anhui?Medical?University?from?January?2019?to?January?2023?were?retrospectively?analyzed.?Patients?were?divided?into?combination?group?(n=35)?and?radiochemotherapy?group?(n=32)?according?to?different?treatment?plans.?Progress?free?survival?(PFS) ......